



## **BIOGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS FEBRUARY 13, 2024**

January 12, 2024

Cambridge, Mass.—[Biogen Inc.](#) (Nasdaq:BIB) today announced it will report fourth quarter and full year 2023 financial results Tuesday, February 13, 2024, before the financial markets open.

Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET. To access the live webcast, please go to the investors section of Biogen's website at [investors.biogen.com](#). An archived version of the webcast will be available for at least 90 days following the presentation.

### **About Biogen**

Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer's disease, the first treatment to target a genetic form of ALS, the first oral treatment approved for postpartum depression, and the first approved treatment for Friedreich's ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.

We routinely post information that may be important to investors on our website at [www.biogen.com](#). Follow us on social media - [Facebook](#), [LinkedIn](#), [X](#), [YouTube](#).

### **Contact:**

Karen Jewell  
Investor Relations  
Biogen  
781.464.2442